These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 12847734)
21. [Physicians and drug industry--one more time]. Rørtveit G Tidsskr Nor Laegeforen; 2008 Feb; 128(5):553. PubMed ID: 18311195 [No Abstract] [Full Text] [Related]
22. The biotech drug market. Lawrence S Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645 [No Abstract] [Full Text] [Related]
23. Adoption agent. Peota C Minn Med; 2005 Mar; 88(3):8-9. PubMed ID: 15852583 [No Abstract] [Full Text] [Related]
24. Biotech drug market steadily expands. Lawrence S Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279 [No Abstract] [Full Text] [Related]
25. Soft targets: nurses and the pharmaceutical industry. Jutel A; Menkes DB PLoS Med; 2008 Feb; 5(2):e5. PubMed ID: 18254652 [TBL] [Abstract][Full Text] [Related]
26. Tysabri back on market. Sheridan C Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111 [No Abstract] [Full Text] [Related]
27. The medical profession and the pharmaceutical industry: when will we open our eyes? Breen KJ Med J Aust; 2004 Apr; 180(8):409-10. PubMed ID: 15089732 [TBL] [Abstract][Full Text] [Related]
28. Making the move into drug sales. Willerroider M Nature; 2004 Jul; 430(6998):486-7. PubMed ID: 15269778 [No Abstract] [Full Text] [Related]
31. Pharmaceutical promotion and GP prescription behaviour. Windmeijer F; de Laat E; Douven R; Mot E Health Econ; 2006 Jan; 15(1):5-18. PubMed ID: 15945041 [TBL] [Abstract][Full Text] [Related]
32. [Economic or medical innovations: that is the question!]. Freitag MH; Wohlgemuth WA Med Klin (Munich); 2006 Jul; 101(7):590-1; author reply 591-3. PubMed ID: 16897896 [No Abstract] [Full Text] [Related]
33. Allergic rhinitis: market evolution. Clark MJ; Million RP Nat Rev Drug Discov; 2009 Apr; 8(4):271-2. PubMed ID: 19337269 [No Abstract] [Full Text] [Related]
34. [Corrupt research may damage public health]. Waldum HL Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2672-3. PubMed ID: 16215620 [No Abstract] [Full Text] [Related]
35. The impact of market volatility on the cell therapy industry. Brindley DA; Reeve BC; Sahlman WA; Bonfiglio GA; Davie NL; Culme-Seymour EJ; Mason C Cell Stem Cell; 2011 Nov; 9(5):397-401. PubMed ID: 22056137 [TBL] [Abstract][Full Text] [Related]
36. The year's new drugs. Graul AI; Prous JR Drug News Perspect; 2005; 18(1):21-36. PubMed ID: 15753973 [TBL] [Abstract][Full Text] [Related]
37. Why is this woman smiling? The hard sell of bad medicine. Bloice C Revolution (Oakl); 2005; 6(1):22-9. PubMed ID: 15822700 [No Abstract] [Full Text] [Related]
39. Mouse platforms jostle for slice of humanized antibody market. Moran N Nat Biotechnol; 2013 Apr; 31(4):267-8. PubMed ID: 23563400 [No Abstract] [Full Text] [Related]
40. The cost of prescription drugs: rising concerns over equity, fairness and access to essential care. Work DR; Domino ME N C Med J; 2003; 64(6):270-4. PubMed ID: 14983614 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]